Eric Dusseux, MD, MSc, MBAChief Executive Officer
Prior to joining Bionik, Dr. Dusseux was President of Europe and a director for Auregen BioTherapeutics SA, a 3D bioprinting tissue engineering biotechnology company headquartered in Switzerland, that he formed while at Bemido SA, a family office, with the support of Gurnet Point Capital and Waypoint.
From 2012 through 2016, Dr. Dusseux served as an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur, the vaccine division of Sanofi. Among other responsibilities, Dr. Dusseux, Vice-President Corporate Strategy, was responsible for business intelligence, strategic and business planning, and corporate development.
Before joining Sanofi Pasteur, Dr. Dusseux served as Vice-President, MAGE-A3 Medicines Development Leader, within the Immunotherapeutics Business Unit at GSK Biologicals, a division of GlaxoSmithKline, in charge of therapeutic vaccines against cancer.
Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from 2002 to 2007.
Dr. Dusseux is a Medical Doctor, specializing in Public Health. Dr. Dusseux also holds a Master of Science in Physical Chemistry and is a graduate of the French Business School H.E.C. in Paris (MBA, Isa).
Michal PrywataCo-Founder and Chief Technology Officer
Mr. Prywata is the co-founder and Chief Technology Officer of Bionik Laboratories. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.
Leslie N. Markow, CPA, CA, CPA (Illinois), C.Dir.Chief Financial Officer
Ms. Markow has served as the Company’s Chief Financial Officer since September 2014. She has over 25 years of finance and accounting leadership experience and holds a CPA and CA in Canada, US CPA (Illinois) and Chartered Director designations. Ms. Markow is the former Chief Financial Officer of Stewardship Ontario and Blue Ocean NutraSciences Inc., and Director of Client Service for Resources Global Professionals, a Nasdaq-listed global consulting firm. For 11 years she held various positions, including Chief Administrative Officer at SunOpta Inc. a Nasdaq/TSX listed public company. Ms. Markow started her career in 1983 with PricewaterhouseCoopers, ultimately holding a position as Senior Audit Manager. She is a member of the Board of Directors and Chairperson of the Audit Committee of Jemtec Inc. Ms. Markow also is a member of Financial Executives Canada, where she is a past National Board Director, Toronto Board Director, Toronto Chapter President and the winner of the Toronto Leadership Award. She is a faculty member of The Directors College, which is a joint venture of McMaster University and The Conference Board of Canada.
Timothy A. McCarthy, MBAChief Commercialization Officer
Timothy A. McCarthy joins the Bionik team having recently served as the Chief Executive Officer of Medical Compression Systems, Inc., a medical device company specializing in compression therapy to prevent DVT and improve wound healing for joint replacement patients. He was recruited as the top executive at MCS to lead a commercial stabilization and turnaround effort in order to prepare the company for an M&A process seeking a strategic partner. Prior to that, Mr. McCarthy served as the President and CEO of iWALK, Inc. (now known as BionX Medical Technologies), a venture backed medical robotics company commercializing the Massachusetts Institute of Technology ("MIT") invented BiOM System, the world's first and only actively powered lower limb bionic prosthesis to normalize gait. While at iWALK, Inc. Mr. McCarthy was responsible for leading the final product development and commercial sales strategy that led to the successful establishment of a long-term market foothold for this new category of healthcare technology products. In addition, Mr. McCarthy served at Össur Americas as Vice President of Sales and Marketing, where he was promoted to the top commercial executive and leader of a sales and marketing restructuring and growth effort, resulting in above budget attainment each year and 4.5x revenue growth during his nine year tenure. Mr. McCarthy also held sales leadership roles at the Chattanooga Group, Inc. (now known as DJO Global). Over the course of his career Mr. McCarthy has proven to be instrumental in the expansion of public, private and startup healthcare technology and medical device companies.
Mr. McCarthy graduated cum laude from Northeastern University with a Bachelor of Science in Business Administration and received his Master of Business Administration from the University of California in Los Angeles.
Malcolm G. BockVice President of Engineering
Mr. Bock previously served as the Vice President of Engineering at Respiratory Motion, where he was responsible for creating a product pipeline and technology roadmap, and bringing the company's first product from concept to launch in 10-months' time. Prior to that, Mr. Bock served as the Senior Director of Global R&D for Covidien Ltd., a spin-off of Tyco International, where he was responsible for R&D and launching 15 new products, including both durable electro-mechanical systems and single-use devices, over a 10-year period. In 2011, he was awarded Covidien Inventor of the Year. Over the course of his career, Mr. Bock has launched over 38 new products and was awarded Best Divisional Vitality Index, and Best New Product for his work at Covidien. He has also been awarded 30 patents, with an additional 28 patents pending.